Opthea Limited (OPT.AX)
| Previous close | 0.6750 |
| Open | 0.6700 |
| Bid | 0.6650 x 1566800 |
| Ask | 0.6950 x 380500 |
| Day's range | 0.6650 - 0.6800 |
| 52-week range | 0.3125 - 0.8150 |
| Volume | |
| Avg. volume | 715,676 |
| Market cap | 447.395M |
| Beta (5Y monthly) | 0.73 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.4700 |
| Earnings date | 28 Feb 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 11 Oct 2004 |
| 1y target est | 7.54 |
Simply Wall St.Owning 39% shares,institutional owners seem interested in Opthea Limited (ASX:OPT),
Key Insights Institutions' substantial holdings in Opthea implies that they have significant influence over the...
GlobeNewswireOpthea Appoints John Han, PharmD, as VP Medical Affairs
Brings extensive experience in retinal and ophthalmology diseasesMELBOURNE, Australia and PRINCETON, N.J., April 08, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced the appointment of John Han, PharmD, to the role of Vice President, Medical Affairs, effective A
- GlobeNewswire
Opthea to Participate in the 23ʳᵈ Annual Needham Virtual Healthcare Conference
MELBOURNE, Australia and PRINCETON, N.J., April 04, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that management will present at the 23rd Annual Needham Virtual Healthcare Conference and participate in one-on-one investor meetings on April 11, 2024. 23rd Ann
